Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.

ABSTRACT:

Background and purpose

Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor-selective agonists.

Experimental approach

Efficacy and safety were assessed in mice with diet-induced obesity (DIO) and those with leptin-deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU-6102) and NMU2 (NMU-2084), along with non-selective NMU1/2 agonists (NMU-0002 and NMU-6014).

SUBMITTER: Nagai H 

PROVIDER: S-EPMC5758400 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature